Pretransplant Immune Checkpoint Inhibitor Treatment for Intermediate-advanced Hepatocellular Carcinoma in Living Donor Liver Transplantation.

ABSTRACT:

Background

The use of immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) is gaining momentum. However, evidence regarding the feasibility and safety of pre-LT ICI therapy remains limited and controversial. This study presents our experience with patients with intermediate-advanced HCC who were downstaged using regimens incorporating ICIs and subsequently underwent living donor LT.

Methods

We retrospectively reviewed the medical records of 10 patients with Barcelona Clinic Liver Cancer stage B or C HCC treated with locoregional therapies (LRTs), ICIs, and living donor LT at Chang Gung Memorial Hospital at Linkou between 2021 and 2024.

Results

In total, 10 recipients rec

SUBMITTER: Cheng CH 

PROVIDER: S-EPMC12448165 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature